Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Perry who wrote (1854)	3/28/1998 1:34:00 PM
From: Matthew Cooper	Read Replies (1) \| Respond to of 4676

How was the SOT meeting in Seattle? I didn't go this year. Do ISIP tox people regularly attend?

To: Perry who wrote (1854)	3/29/1998 4:31:00 AM
From: SnowShredder	Read Replies (1) \| Respond to of 4676

The two techniques are similar...and very promising. A delivery vehicle is not necessary...via direct injection, but there is a low efficiency of gene transfer and a low level of stable integration. Thus in proliferating cells repeated injections may be required. In tissue that does not regularly proliferate, the injected DNA may be expressed for months. If one uses an integrative vector (eg.retroviral) then long-term production of anti-sense RNA may be obtained. I hope this helps. Best of Luck, Where'd He Go?